NCT03762200View on ClinicalTrials.gov

SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects

NACompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

December 2, 2019

Study Completion Date

June 3, 2020

Conditions
Hemorrhage
Interventions
DEVICE

SURGICEL Powder

SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material

Trial Locations (8)

3600

Ziekenhuis Oost Limburg, Genk

9000

Universitair Ziekenhuis Gent, Ghent

EH4 2XU

NHS Lothian (Western General Hospital), Edinburgh

CB2 0QQ

Cambridge University Hospitals NHS Trust (Addenbrooke's Hospital), Cambridge

G81 4DY, GB

Golden Jubilee National Hospital, Clydebank

LS9 7TF

Leeds Teaching Hospitals NHS Trust (St James's University Hospital), Leeds

NE7 7DN

Newcastle upon Tyne NHS Foundation Trust (Freeman Hospital), Newcastle upon Tyne

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT03762200 - SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects | Biotech Hunter | Biotech Hunter